Table 2.

Overview of studies in systematic review, grouped according to outcome data from virology and immunology response and serious drug- related AEs

Authors and publish time	Virology and immunologic response		Serious drug- related AEs
	Experiment group,  % (n/N)	Control group, n (%)	Experiment group, n (%)	Control group, n (%)
Jan van Lunzen et al. 2012. [20]	10 mg: 91 % (48/53) 25 mg: 88 % (45/51) 50 mg: 90 % (46/5150)	EFV (600 mg): 82 % (41/50)	0	2 % (1/50)
Pedro Cahn et al. 2013. [23]	50 mg: 71 % (251/354,378)	RAL (400 mg): 64 % (230/414)	1 % (2/378)	1 % (4/414)
Francois Raffi et al. 2013. [21]	50 mg: 88 % (361/411)	RAL (400 mg): 85 % (351/411)	<1 % (3/411)	1 % (5/411)
S. Walmsley et al. 2013. [22]	50 mg: 88 % (364/414)	RAL (400 mg): 81 % (338/419)	<1 % (1/414)	2 % (8/419)

DTG dolutegravir, S/GSK1349572; RAL raltegravir; EFV efavirenz